Empagliflozin, an essential medication that was previously expensive, will soon be made available by domestic pharmaceutical companies at much reduced pricing, which is good news for the millions of Indians who suffer from diabetes.
This comes as Indian companies are now able to market the medicine under their names after the German pharmaceutical major Boehringer Ingelheim’s patent expired on March 11.
Prominent pharmaceutical firms like Mankind Pharma, Torrent, The Alkem, Dr. Reddy, and Lupin are among them. Particularly, Mankind Pharma plans to sell the medication for 90% less than the leading business.
In the treatment of diabetes and its related disorders, including heart disease and chronic kidney disease, empagliflozin is essential. In India, more than 10.1 crore individuals have diabetes, and many of them must pay for their own medications. Patients benefit greatly from this price decrease in terms of their financial situation.
Experts stress that empagliflozin is essential for postponing renal failure and avoiding heart failure. But in the past, accessibility has been hampered by its high cost. Millions of people stand to gain a great deal from the more reasonably priced solutions offered by Indian businesses.
Boehringer Ingelheim has sold three branded Empagliflozin medications to Torrent Pharmaceuticals. Mankind Pharma credits the use of premium, USFDA-certified raw materials and the production of its Active Pharmaceutical Ingredient (API) with enabling it to further cut expenses.
Diabetes has a significant financial impact in India, and patients frequently have to pay for their medications due to a lack of insurance coverage. For diabetes people nationwide, the lower cost of empagliflozin is a great comfort.
